N-(4- 18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 679-686

  Di Gialleonardo, Valentina ^a,b   Signore, Alberto ^a,b,c   Glaudemans, Andor W J M ^a   Dierckx, Rudi A J O ^a   De Vries, Erik F J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

18F SFB; Inflammation imaging; Interleukin 2; Labeling; T lymphocytes

Indexed keywords

ALCOHOL; BORIC ACID; BUFFER; CHLOROACETIC ACID; INTERLEUKIN 2 RECEPTOR; ISOTOPE; N (4 FLUOROBENZOYL)INTERLEUKIN 2 F 18; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; OXYGEN 18; PHYTOHEMAGGLUTININ; RADIOPHARMACEUTICAL AGENT; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; WATER; BENZOIC ACID DERIVATIVE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INTERLEUKIN 2; N (4 FLUOROBENZOYL)INTERLEUKIN 2; N SUCCINIMIDYL 4 FLUOROBENZOATE; N-(4-FLUOROBENZOYL)INTERLEUKIN-2; N-SUCCINIMIDYL-4-FLUOROBENZOATE; SUCCINIMIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BINDING AFFINITY; BINDING ASSAY; BLADDER; DRUG BINDING; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; INCUBATION TIME; INOCULATION; ISOTOPE LABELING; KIDNEY; KIDNEY CLEARANCE; MASS SPECTROMETRY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITRON EMISSION TOMOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; RADIOCHEMISTRY; RECEPTOR BINDING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCID MOUSE; SOLID PHASE EXTRACTION; T LYMPHOCYTE ACTIVATION; WHOLE BODY IMAGING; ANIMAL; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DRUG EFFECT; METABOLISM; METHODOLOGY; REPRODUCIBILITY; SCINTISCANNING; T LYMPHOCYTE;

ANIMALS; BENZOATES; CELL PROLIFERATION; DRUG STABILITY; HUMANS; INTERLEUKIN-2; MICE; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SUCCINIMIDES; T-LYMPHOCYTES;

EID: 84860761137     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.091306     Document Type: Article

References (39)

1. Cohen FE, Kosen PA, Kuntz ID, Epstein LB, Ciardelli TL, Smith KA. Structureactivity studies of interleukin-2. Science. 1986;234:349-352.
2. Annovazzi A, D'Alessandria C, Bonanno E, et al. Synthesis of 99mTc-HYNICinterleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes. Eur J Nucl Med Mol Imaging. 2006;33:474-482.
3. Malviya G, de Vries EF, Dierckx RA, Signore A. Synthesis and evaluation of 99mTc-labelled monoclonal antibody 1D09C3 for molecular imaging of major histocompatibility complex class II protein expression. Mol Imaging Biol. 2011;13:930-939.
4. Signore A, Parman A, Pozzilli P, Andreani D, Beverley PC. Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123I-interleukin-2: An early sign of type 1 diabetes. Lancet. 1987;2:537-540. (Pubitemid 17126038)
5. Signore A, Chianelli M, Annovazzi A, et al. Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet. Eur J Nucl Med. 2000;27:18-24. (Pubitemid 30097255)
6. Signore A, Picarelli A, Annovazzi A, et al. 123I-Interleukin-2: Biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun. 2003;24:305-316.
7. Annovazzi A, Biancone L, Caviglia R, et al. 99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging. 2003;30:374-382. (Pubitemid 36692862)
8. Annovazzi A, Bonanno E, Arca M, et al. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2006;33:117-126. (Pubitemid 43152877)
9. Vaidyanathan G, Zalutsky MR. Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nat Protoc. 2006;1:1655-1661. (Pubitemid 46773286)
10. Wester HJ, Hamacher K, Stocklin G. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol. 1996;23:365-372. (Pubitemid 26164971)
11. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem. 1988;60:2299-2301.
12. Bøyum A. Separation of white blood cells. Nature. 1964;204:793-794.
13. Lotze MT, Robb RJ, Sharrow SO, Frana LW, Rosenberg SA. Systemic administration of interleukin-2 in humans. J Biol Response Mod. 1984;3:475-482. (Pubitemid 14013608)
14. Gordon I, Vivian G. Radiolabelled leucocytes: A new diagnostic tool in occult infection/inflammation. Arch Dis Child. 1984;59:62-66. (Pubitemid 14154192)
15. Rövekamp MH, Hardeman MR, van der Schoot JB, Belfer AJ. 111Indium-labelled leucocyte scintigraphy in the diagnosis of inflammatory disease-first results. Br J Surg. 1981;68:150-153. (Pubitemid 11136401)
16. Barrera P, van der Laken CJ, Boerman OC, et al. Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2000;39:870-874. (Pubitemid 30649513)
17. Blankenberg FG, Kalinyak J, Liu L, et al. 99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody. Eur J Nucl Med Mol Imaging. 2006;33:566-574.
18. Dancey G, Violet J, Malaroda A, et al. A phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma. Clin Cancer Res. 2009;15:7701-7710.
19. Malviya G, D'Alessandria C, Bonanno E, et al. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes. J Nucl Med. 2009;50:1683-1691.
20. van der Laken CJ, Boerman OC, Oyen WJ, van de Ven MT, van der Meer JW, Corstens FH. Imaging of infection in rabbits with radioiodinated interleukin-1 (alpha and beta), its receptor antagonist and a chemotactic peptide: A comparative study. Eur J Nucl Med. 1998;25:347-352. (Pubitemid 28211597)
21. Blockmans D, Bley T, Schmidt W. Imaging for large-vessel vasculitis. Curr Opin Rheumatol. 2009;21:19-28.
22. Lehmann P, Buchtala S, Achajew N, et al. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin Rheumatol. 2011;30:37-42.
23. Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis? J Nucl Med. 1994;35:1650-1652.
24. Imperiale A, Riehm S, Veillon F, Namer IJ, Braun JJ. FDG PET coregistered to MRI for diagnosis and monitoring of therapeutic response in aggressive phenotype of sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38:983-984.
25. Beckers C, Jeukens X, Ribbens C, et al. 18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging. 2006;33:275-280.
26. Brenner W. 18F-FDG PET in rheumatoid arthritis: There still is a long way to go. J Nucl Med. 2004;45:927-929. (Pubitemid 47611677)
27. dos Anjos DA, do Vale GF, Campos Cde M, et al. Extra-articular inflammatory sites detected by F-18 FDG PET/CT in a patient with rheumatoid arthritis. Clin Nucl Med. 2010;35:540-541.
28. Däbritz J, Jasper N, Loeffler M, Weckesser M, Foell D. Noninvasive assessment of pediatric inflammatory bowel disease with 18F-fluorodeoxyglucose- positron emission tomography and computed tomography. Eur J Gastroenterol Hepatol. 2011;23:81-89.
29. Löffler M, Weckesser M, Franzius C, Schober O, Zimmer KP. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci. 2006;1072:379-385. (Pubitemid 44448470)
30. Pio BS, Byrne FR, Aranda R, et al. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-Dglucose-labeled white blood cells. Mol Imaging Biol. 2003;5:271-277. (Pubitemid 37074878)
31. Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M. PET/CT in the evaluation of inflammatory bowel disease: Studies in patients before and after treatment. Mol Imaging Biol. 2010;12:85-88.
32. Chen W, Dilsizian V. 18F-fluorodeoxyglucose PET imaging of coronary atherosclerosis and plaque inflammation. Curr Cardiol Rep. 2010;12:179-184.
33. Chung SY, Lee JH, Kim TH, Kim SJ, Kim HJ, Ryu YH. 18F-FDG PET imaging of progressive massive fibrosis. Ann Nucl Med. 2010;24:21-27.
34. Coulson JM, Rudd JH, Duckers JM, et al. Excessive aortic inflammation in chronic obstructive pulmonary disease: An 18F-FDG PET pilot study. J Nucl Med. 2010;51:1357-1360.
35. Hiari N, Rudd JH. FDG PET imaging and cardiovascular inflammation. Curr Cardiol Rep. 2011;13:43-48.
36. Kai H. Novel non-invasive approach for visualizing inflamed atherosclerotic plaques using fluorodeoxyglucose-positron emission tomography. Geriatr Gerontol Int. 2010;10:1-8.
37. Signore A, Chianelli M, Ronga G, Pozzilli P, Beverley PC. In vivo labelling of activated T lymphocytes by i.v. injection of 123I-IL2 for detection of insulitis in type 1 diabetes. Prog Clin Biol Res. 1990;355:229-238.
38. Signore A, Chianelli M, Annovazzi A, et al. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med. 2000;41:242-249. (Pubitemid 30091342)
39. Meller S, Gilliet M, Homey B. Chemokines in the pathogenesis of lichenoid tissue reactions. J Invest Dermatol. 2009;129:315-319.